The Department of War requires urgent support to evaluate and secure the domestic manufacturing base for military-essential medications, addressing a critical supply chain vulnerability. The effort involves independent technical, regulatory, and economic due diligence assessments of proposed domestic pharmaceutical manufacturing solutions. The outcome will be a strategic roadmap and financial underwriting analysis to rapidly secure the essential medical supply chain without foreign reliance. No specific timelines, budget amounts, or performance location are mentioned in the description. The government has determined this need is of unusual and compelling urgency, pursuing a sole source procurement.